Drupal.behaviors.print = function(context) {window.print();window.close();}>
QUASAR Study Shows Oncotype DX Gauges Colon Cancer Recurrence Risk, Doesn't Predict Treatment Benefit
November 09, 2011
QUASAR Study Shows Oncotype DX Gauges Colon Cancer Recurrence Risk, Doesn't Predict Treatment Benefit
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
TGen, Genomic Health ID Potential Oxaliplatin Response Genes; Findings May Enhance Colon Cancer Test
January 19, 2011 / Pharmacogenomics Reporter
Genomic Health Accelerates Timeline for Prostate Cancer Test
January 10, 2011 / GenomeWeb Daily News
Deal with NewBridge Allows Genomic Health to Expand Oncotype DX into Africa, Middle East
August 13, 2012 / GenomeWeb Daily News
Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance
July 3, 2012 / Pharmacogenomics Reporter
MDx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 13, 2012 / Pharmacogenomics Reporter